A Phase 2 interventional study of Sonrotoclax and Zanubrutinib in Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent and Waldenstrom's Macroglobulinemia Refractory, sponsored by BeOne Medicines. Active, not recruiting at 72 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by BeOne Medicines · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Waldenstrom Macroglobulinemia by BeOne Medicines — 3 open to participants now, 5 under way, none of them phase 3. Waldenstrom Macroglobulinemia · BeOne Medicines.
Among the 10 studies in Waldenstrom Macroglobulinemia by BeOne Medicines, this one is one of 2 that started in 2023, is one of 3 in phase 2, and was the 9th registered.
524 studies on the registry are indexed under Waldenstrom Macroglobulinemia; 61 are open to participants now.
Browse Waldenstrom Macroglobulinemia studies →3 of the 10 studies in Waldenstrom Macroglobulinemia by BeOne Medicines are open now, in 12 countries. Recruiting first, the newest first:
BeiGene · Sites in United States, Puerto Rico
Ages 18+
BeOne Medicines · Sites in China
Ages 18+
BeOne Medicines · Sites in United States, Australia, Brazil and 13 more countries
Ages 18+
By country, each count listing its studies:
Of the 47 Waldenstrom Macroglobulinemia studies recruiting now, 43 (91%) set no upper age limit and 1 (2%) stops at 75 or younger; 2 take children under 18; none take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 1 · Phase 4 1
First in 2017; this study’s year is marked. 2 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 114 is above the median of 39 across 429 interventional studies indexed under Waldenstrom Macroglobulinemia.
Median enrollment 105 across the 8 interventional studies, 111 across the 1 observational. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
BeOne Medicines is the lead sponsor of 69 studies on the registry; 49 are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
3 of the studies in Waldenstrom Macroglobulinemia by BeOne Medicines that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05640102BeiGeneObservational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia | 2026-12 |
| NCT05006716BeOne MedicinesA Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies | 2027-03 |
| NCT05294731BeOne MedicinesTreatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies in Waldenstrom Macroglobulinemia by BeOne Medicines, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety and efficacy of the BCL2 inhibitor sonrotoclax (BGB-11417) in participants with relapsed/refractory Waldenström's Macroglobulinemia (R/R WM) and in combination with zanubrutinib in adult participants with previously untreated WM.
This study will test whether sonrotoclax (BGB-11417) can be used to improve outcomes in participants with Waldenström's Macroglobulinemia (WM) both when used alone in those who have not responded well to conventional treatments and when used in combination with zanubrutinib in those who have not yet received treatment. The main goals of the study are to determine how many participants no longer have evidence of cancer or have some improvement in the signs and symptoms of cancer after treatment, and to determine what adverse events, or side effects, participants might experience.
BCL2 is a key protein involved in cell death, and abnormal levels of BCL2 are associated with many cancers. Blocking the action of BCL2 proteins is a promising approach with potential therapeutic benefits in participants with different types of cancers, including WM. This study will enroll approximately 105 participants. All participants will receive sonrotoclax orally as a tablet.
The study will take place at multiple centers worldwide. The overall time to participate in this study is approximately 5 years.
Note: Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with R/R disease to both Bruton tyrosine kinase (BTK) inhibitor and anti-CD20 antibody-based systemic therapy containing chemotherapy or proteasome inhibitor will receive sonrotoclax at a standard dose, given orally once daily.
Drug: Sonrotoclax
Participants with R/R disease to anti-CD20 antibody-based systemic therapy containing chemotherapy or proteasome inhibitor and were intolerant to BTK inhibitor will receive sonrotoclax at a standard dose, given orally once daily.
Drug: Sonrotoclax
Participants with R/R disease to a BTK inhibitor treatment and are unsuitable for chemoimmunotherapy will receive sonrotoclax at a standard dose, given orally once daily.
Drug: Sonrotoclax
Participants with previously untreated WM will receive sonrotoclax and zanubrutinib combination therapy for a fixed duration.
Drug: Sonrotoclax · Drug: Zanubrutinib
Administered orally as a tablet.
Also known as: BGB-11417
Administered orally as a capsule.
Also known as: BRUKINSA, BGB-3111
Cohort 1: Major Response Rate (MRR)
MRR is defined as the percentage of participants achieving partial response (PR) or better, as assessed by the Independent Review Committee (IRC) per the 11th International Workshop on Waldenström Macroglobulinemia (IWWM-11) WM response criteria.
Time frame: Up to approximately 4 years
Cohorts 2 and 3: MRR as assessed by the IRC
MRR is defined as the percentage of participants achieving PR or better.
Time frame: Up to approximately 5 years
All Cohorts: MRR as assessed by the Investigator
MRR is defined as the percentage of participants achieving PR or better.
Time frame: Up to approximately 5 years
Cohorts 1, 2, and 3: Duration of Major Response (DoMR) as assessed by the IRC
DoMR is defined as the time from first determination of major response until first documentation of progression or death, whichever occurs first.
Time frame: Up to approximately 5 years
All Cohorts: DoMR as assessed by the Investigator
DoMR is defined as the time from first determination of major response until first documentation of progression or death, whichever occurs first.
Time frame: Up to approximately 5 years
Cohorts 1, 2, and 3: Complete Response (CR) + Very Good Partial Response (VGPR) as assessed by the IRC
CR + VGPR is defined as the percentage of participants who achieve CR or VGPR.
Time frame: Up to approximately 5 years
All Cohorts: CR + VGPR as assessed by the Investigator
CR + VGPR is defined as the percentage of participants who achieve CR or VGPR.
Time frame: Up to approximately 5 years
Cohorts 1, 2, and 3: Overall Response Rate (ORR) as assessed by the IRC
ORR is defined as the percentage of participants with minor response (MR) or better.
Time frame: Up to approximately 5 years
All cohorts: ORR as assessed by the investigator
ORR is defined as the percentage of participants with MR or better.
Time frame: Up to approximately 5 years
Cohorts 1, 2, and 3: Duration of Response (DOR) as assessed by the IRC
DOR is defined as the time from first determination of response until first documentation of progression or death, whichever occurs first.
Time frame: Up to approximately 5 years
All Cohorts: DOR as assessed by the investigator
DOR is defined as the time from first determination of response until first documentation of progression or death, whichever occurs first.
Time frame: Up to approximately 5 years
Cohorts 1, 2, and 3: Progression-Free Survival (PFS)
PFS is defined as the time from first dose until first documentation of progression or death, whichever comes first, as assessed by the IRC and by the investigator.
Time frame: Up to approximately 5 years
Cohorts 1, 2, and 3: Time to major response as assessed by the IRC
Time to major response is defined as the time from start of study treatment to the first documentation of major response.
Time frame: Up to approximately 5 years
All Cohorts: Time to major response as assessed by the investigator
Time to major response is defined as the time from start of study treatment to the first documentation of major response.
Time frame: Up to approximately 5 years
Cohorts 1, 2, and 3: Overall Survival (OS)
OS is defined as the time from first study drug administration to the date of death due to any cause.
Time frame: Up to approximately 5 years
Cohort 4: Time to next treatment
Defined as the time from the start of treatment to the start of first subsequent therapy for WM.
Time frame: Up to approximately 5 years
Number of participants reporting adverse events
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), including laboratory abnormalities, physical examination results, and vital signs.
Time frame: Up to approximately 5 years
All Cohorts: Change from Baseline in Health-Related Quality of Life (HRQoL): NFLymSI-18 Disease-related Symptoms-Physical and Treatment-Related Side Effects Subscales
HRQoL based on participant-reported outcomes using National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Lymphoma Cancer Symptom Index - 18 Item (NFLymSI-18) Version 4. The questionnaire contains 18 items, each of which utilizes a Likert scale with 5 possible responses ranging from 0 'Not at all' to 4 'Very much' and is divided into a total score.
Time frame: Baseline and approximately months 7, 13, 19, and 25
Plan to share: Yes — BeOne shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeOne shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeOne review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: See plan description
Access criteria: See plan description
Data sharing details ↗ · beonemedicines.com
No publications or documents are linked to this record.
Ran from Oct 2023 to primary completion in Sep 2026, 34 months.
Of 66 phase 2 interventional studies under Waldenstrom Macroglobulinemia, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 103. This study's 34 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sonrotoclax
Waldenstrom Macroglobulinemia →